TechGuru,

I 100% agree. Cancer progress has taken longer than we would like, but the science behind VX/LL having a significant impact in multiple cancers remains solid and represents an astronomical potential.

For some of the newer CYDY investors, here is a post I put together in April 2019 that highlights some of this US Cancer Potential:

https://investorshangout.com/post/view?id=5411546

Additionally, I recommend anyone who hasn't already, read the two marked posts from trding (from the top of the website not mobile app) and "The Expanding Therapeutic Perspective of CCR5 Blockade" (linked below) to develop your own picture of VX/LL longer term potential. While CD12/COVID has created a somewhat binary event in the near term, it truly is a bonus indication that none of us expected a year ago.

https://www.frontiersin.org/articles/10.3389/...01981/full

Last but not least, the NobleCon 2019 presentation is well worth the hour watch if you haven't seen it yet. RP may be a sore subject, but he is still standing behind the science and/or VX/LL.....which I'd wager is why 98+% are still invested in CYDY (VX/LL, not RP).

Best of luck to all longs!